March 23, 2026
RA Jainee
DSP Healthcare Fund – Direct | Growth
📌 Fund Snapshot & Key Details
| Particulars | Details |
|---|---|
| Fund House | DSP Mutual Fund |
| Scheme Type | Open-ended |
| Category | Equity: Sectoral – Healthcare |
| Benchmark | BSE Healthcare TRI |
| Launch Date | 30 November 2018 |
| Plan / Option | Growth, IDCW |
| NAV Growth (Rs.) | 40.21 |
| NAV IDCW (Rs.) | 23.25 |
| Minimum Investment (Rs.) | 100 |
| Minimum SIP Investment (Rs.) | 100 |
| Exit Load | 0.5% if redeemed within 1 month |
| Lock-in Period | NA |
| Riskometer | Very High |
| AUM (Rs.) | 3,033 Cr |
| Expense Ratio | 0.65% |
⚖️ Sahifund Review
PLUS
• Strong long-term performance with ~22.27% CAGR (3Y) and ~15.81% (5Y)
• Cost-efficient fund with relatively low expense ratio (0.65%)
• Diversified exposure across pharma, diagnostics and healthcare ecosystem
• Benefits from long-term growth in CDMO, specialty pharma and exports
• Experienced fund management with disciplined stock selection
MINUS
• Pure sectoral fund — very high concentration risk (~98% healthcare exposure)
• Weak short-term performance (-1.58% 1Y) shows momentum lag
• Portfolio valuations elevated (P/E ~32.77), limiting near-term upside
• Average category ranking vs top pharma funds
• Highly dependent on global pharma cycle and regulatory environment
Sahifund View (Decisive Line)
A strong long-term healthcare fund, but suitable only for SIP-based investors with high risk appetite — not for short-term or diversified allocation.
👉 Apply Online | Ask Us MF Queries |
⏱️ Last Updated: 24 March 2026, 10.00 AM
📊 Sahifund Interpretation of the Benchmark
BSE Healthcare TRI
The BSE Healthcare TRI reflects the performance of pharmaceutical and healthcare companies in India, heavily influenced by export-driven pharma players.
Benchmark Behaviour Snapshot
• Strong performance during pharma export and CDMO growth cycles
• High sensitivity to USFDA approvals and global demand
• Defensive during broader market corrections but cyclical in nature
• Concentrated exposure to large-cap pharma companies
Sahifund Insight:
Healthcare funds outperform during sector cycles but lag when broader markets rally.
🧠 Investment Strategy – Explained Simply
The scheme aims to generate long-term capital appreciation by investing in equity and equity-related securities of pharmaceutical and healthcare companies.
➡️ In simple words:
You are investing in a basket of pharma and healthcare companies benefiting from rising global healthcare demand and outsourcing trends.
👤 Sahifund Interpretation of Fund Managers & Their Performance
Chirag Dagli
Chartered Accountant with experience across HDFC AMC, ICICI Securities and global institutions, bringing strong sectoral expertise.
Sahifund Assessment:
Performance depends heavily on sector timing and stock selection due to cyclical nature of pharma.
🎯 Suitable for Which Investors?
Suitable if you:
• Want exposure to India’s healthcare and pharma growth story
• Can handle high volatility and sector cycles
• Prefer SIP-based investing approach
• Have a long-term horizon (7+ years)
Avoid if you:
• Prefer diversified equity funds
• Are conservative or new investors
• Expect stable short-term returns
• Already have heavy pharma exposure
❓ Should You Invest in This Fund?
Yes — but selectively.
DSP Healthcare Fund is best used as a satellite allocation to capture long-term healthcare growth. However, due to high concentration and cyclical behaviour, investments should be staggered via SIP.
Final Word:
A powerful sectoral bet — but only for disciplined, long-term investors.
⚠️ Disclaimer
Mutual fund investments are subject to market risks. Read all scheme-related documents carefully.